BSE Live
Apr 10, 16:01Prev. Close
4748.55
Open Price
4782.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 16:00Prev. Close
4749.10
Open Price
4750.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
4868.60 (7)
| Key Financial Ratios of Pfizer (in Rs. Cr.) | Nov 04 | |
| Per Share Ratios | ||
| Basic EPS (Rs.) | 15.81 | |
| Diluted EPS (Rs.) | 15.81 | |
| Cash EPS (Rs.) | 19.37 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 118.65 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 118.65 | |
| Dividend / Share(Rs.) | 10.00 | |
| Revenue from Operations/Share (Rs.) | 220.83 | |
| PBDIT/Share (Rs.) | 29.73 | |
| PBIT/Share (Rs.) | 26.17 | |
| PBT/Share (Rs.) | 25.89 | |
| Net Profit/Share (Rs.) | 15.81 | |
| Profitability Ratios | ||
| PBDIT Margin (%) | 13.46 | |
| PBIT Margin (%) | 11.85 | |
| PBT Margin (%) | 11.72 | |
| Net Profit Margin (%) | 7.15 | |
| Return on Networth / Equity (%) | 13.32 | |
| Return on Capital Employed (%) | 13.01 | |
| Return on Assets (%) | 8.60 | |
| Total Debt/Equity (X) | 0.04 | |
| Asset Turnover Ratio (%) | 120.25 | |
| Liquidity Ratios | ||
| Current Ratio (X) | 2.10 | |
| Quick Ratio (X) | 1.69 | |
| Inventory Turnover Ratio (X) | 8.61 | |
| Dividend Payout Ratio (NP) (%) | 65.56 | |
| Dividend Payout Ratio (CP) (%) | 53.50 | |
| Earnings Retention Ratio (%) | 34.44 | |
| Cash Earnings Retention Ratio (%) | 46.50 | |
| Valuation Ratios | ||
| Enterprise Value (Cr.) | 1,526.73 | |
| EV/Net Operating Revenue (X) | 2.40 | |
| EV/EBITDA (X) | 17.83 | |
| MarketCap/Net Operating Revenue (X) | 2.64 | |
| Retention Ratios (%) | 34.43 | |
| Price/BV (X) | 4.90 | |
| Price/Net Operating Revenue | 2.64 | |
| Earnings Yield | 0.03 |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth